Outcome of the Board Meeting held on 18.03.2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.5 pts less than Nifty Microcap 250 and 1.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Godavari Drugs Ltd's board approved the allotment of 23,60,065 convertible warrants to promoter group members at Rs.89 each, aggregating to about Rs.21 crore, with 25% subscription money (Rs.5.25 crore) already received. Separately, 25,96,935 equity shares were allotted at Rs.89 per share (including Rs.79 premium over the Rs.10 face value), totalling about Rs.23.11 crore, to a mix of promoter and non-promoter allottees. The non-promoter list includes several HNIs, LLPs, and corporate bodies such as SVAN Velocity Fund, Suryatej Advisors LLP, and Satya Foundation. The combined fundraise is roughly Rs.44.12 crore on a preferential basis, with BSE in-principle approval already secured on March 4, 2026.
This preferential allotment will dilute existing shareholders but signals promoter confidence since promoter group entities are also putting in money. Fresh capital of about Rs.44 crore should strengthen the balance sheet, though the stock may see some near-term dilution pressure.